Upstream Bio (UPB) EBITDA Margin (2023 - 2026)
Upstream Bio (UPB) recorded quarterly EBITDA Margin of 4218.09% in Q1 2026, up 38.97% quarter-over-quarter from 6911.23% in Q4 2025, and up 143792.0% on a YoY basis from N/an in Q1 2025.
Upstream Bio (UPB) EBITDA Margin (2023 - 2026) Analysis & Trends
Upstream Bio's EBITDA Margin history runs 4 years deep, the most recent figure standing at 4218.09% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 143792.0% year-over-year to 4218.09%; the TTM figure through Mar 2026 stood at 5176.49% (down 104914.0% YoY), while the FY2025 annual figure was 5618.82%, down 233763.0% from the prior year.
- EBITDA Margin was 4218.09% for Q1 2026 at Upstream Bio, up from 6911.23% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1511.43% in Q3 2023 to a low of 6911.23% in Q4 2025.
- Historically, EBITDA Margin has averaged 4085.84% across 4 years, with a median of 4218.09% in 2026.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin plunged 331023 bps in 2025, then soared 143792 bps in 2026.
- A 4-year view of EBITDA Margin shows it stood at 3184.44% in 2023, then tumbled by 35 bps to 4293.31% in 2024, then tumbled by 61 bps to 6911.23% in 2025, then soared by 39 bps to 4218.09% in 2026.
- The last three EBITDA Margin figures came in at 4218.09% (Q1 2026), 6911.23% (Q4 2025), and 5539.39% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn | -4,218.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,218.09% |
| Dec 31, 2025 | -6,911.23% |
| Sep 30, 2025 | -5,539.39% |
| Jun 30, 2025 | -4,732.87% |
| Mar 31, 2025 | -5,656.01% |
| Dec 31, 2024 | -4,293.31% |
| Sep 30, 2024 | -3,112.52% |
| Jun 30, 2024 | -3,439.22% |
| Mar 31, 2024 | -2,345.78% |
| Dec 31, 2023 | -3,184.44% |
| Sep 30, 2023 | -1,511.43% |